Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s stock price rose 5.7% on Monday . The company traded as high as $19.58 and last traded at $19.58. Approximately 143,934 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 868,986 shares. The stock had previously closed at $18.53.
Wall Street Analyst Weigh In
MTSR has been the topic of a number of analyst reports. Cantor Fitzgerald started coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Bank of America assumed coverage on Metsera in a report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target on the stock. Guggenheim assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price target on the stock. Finally, Evercore ISI began coverage on shares of Metsera in a report on Tuesday, February 25th. They set an "outperform" rating for the company.
Read Our Latest Stock Analysis on Metsera
Metsera Price Performance
The business's 50 day moving average is $23.09.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new stake in shares of Metsera in the first quarter valued at about $884,000. New York State Common Retirement Fund acquired a new position in Metsera in the 1st quarter valued at approximately $131,000. Alphabet Inc. acquired a new position in Metsera in the 1st quarter valued at approximately $135,059,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Metsera in the 1st quarter worth approximately $13,111,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
